S

Sartorius

Bioprocess and laboratory solutions provider

Industrial Management Apprentice

Summer 2027Updated on 10/15/2026
€6.67 - €7.59/hr+ Holiday pay + Christmas bonus
Internship
Göttingen, Germany+1 moreMore locations: Guxhagen, Germany
In Person
Operations & LogisticsProduction Planning & Scheduling

About the job

Requirements
  • Demonstrate a strong interest in business and economics.
  • Have organizational skills and the ability to handle tasks in a structured and independent manner.
  • Work flexibly and reliably.
  • Communicate effectively and work well in a team.
  • Have very good knowledge of English, German, and mathematics, and confidently use MS Office applications.
Responsibilities
  • Rotate through various departments according to a structured training plan to learn workflows and processes and contribute to projects, including international projects.
  • Learn and assist in core commercial functions, including marketing, purchasing, logistics, financial accounting, and human resources.
  • Plan, control, and monitor production processes and prepare calculations, invoices, and quotation comparisons.
  • Maintain customer contacts and support administrative and organizational tasks.

About the company

S

Sartorius

View
Website

Sartorius provides laboratory and bioprocessing equipment and services for the biopharmaceutical industry. Its two divisions, Bioprocess Solutions and Lab Products & Services, supply systems, consumables, and analytics used in biotech drug and vaccine development and production. It differentiates itself with a long history, an integrated portfolio, global support, and acquisitions like BioOutsource to offer end-to-end solutions. Its goal is to help biopharmaceutical companies develop and manufacture biotech products more reliably and at scale.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Göttingen, Germany

Founded

1870

Get referred to Sartorius

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • H1 2026 operational sales rose 7.7%, and management reaffirmed full-year guidance.
  • May 2026 bond refinancing lowered funding pressure before the €650 million maturity.
  • ElevateBio pilot validation and September 2026 ordering support Eveo sales conversion in 2027.

What critics are saying

  • Tariff refunds and customer compensation cut 2026 revenue by up to €35 million.
  • Lab Products grew only 5.3% operationally in H1 2026, lagging Bioprocess Solutions.
  • Delayed advanced-therapy orders from two customers shift revenue into 2027, hurting execution confidence.

What makes Sartorius unique

  • Eveo launches March 16, 2026, integrating cell therapy manufacturing and QC in one system.
  • Bioprocess Solutions dominates with high-recurring consumables and switching costs across biologics manufacturing.
  • Stedim Biotech integration gives Sartorius tighter control over single-use bioprocessing and global customer relationships.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Flexible Work Hours
  • Wellness Program
  • Professional Development Budget

Company News

Yahoo Finance
Jul 23rd, 2026
Sartorius reports 7.7% sales growth as bioprocess equipment stabilises

Sartorius reported solid first-half results, with constant-currency sales up 7.7% and underlying EBITDA rising 3.9% as margins improved to 30.3%. Management confirmed full-year guidance. Bioprocess Solutions led performance, growing 8.3% in constant currencies. Consumables drove growth, whilst equipment stabilised slightly. Chief executive Michael Grosse said demand for biologics remains robust, particularly in monoclonal antibody manufacturing. However, advanced-therapy orders from two customers were delayed and could shift revenue into 2027. Tariff refunds and accounting effects distorted reported results but did not change underlying business trends. The company booked €26 million in customer compensation related to tariffs. Operating cash flow and free cash flow both improved sharply in the first half.

AD HOC NEWS
May 15th, 2026
Sartorius completes full takeover of Stedim Biotech, delisting bioprocessing unit from Euronext Paris

Sartorius Stedim Biotech is set to be delisted from Euronext Paris following a squeeze-out by majority shareholder Sartorius Group. The voluntary tender offer and subsequent acquisition process, which began in early 2024, will transition the company from a separately traded stock into a fully integrated part of Sartorius Group. Headquartered in Aubagne, France, Sartorius Stedim Biotech develops bioprocessing equipment and single-use technologies for biopharmaceutical manufacturing. Its products include bioreactors, filtration systems and process automation tools used by pharmaceutical and biotech companies globally. North America represents a key market, with many US-based biopharma firms using its technologies. The company experienced normalised growth following pandemic-era demand surges, with customers working through elevated inventories accumulated during vaccine production. Despite short-term headwinds, long-term demand drivers remain supported by expanding biologics and advanced therapy pipelines.

wallstreet:online AG
May 6th, 2026
Sartorius completes $560M bond placement with 3.75% coupon to refinance existing debt

Sartorius has completed a €500 million bond placement via its Dutch subsidiary Sartorius Finance B.V. The five-year bond, targeted at institutional investors, was more than four times oversubscribed and carries a 3.75% annual coupon. The life science group will use the proceeds for general corporate purposes, including refinancing existing debt. This includes the redemption of a €650 million bond with a 4.25% interest rate due in autumn 2026. Sartorius has applied for admission to trading on the Euro MTF market of the Luxembourg Stock Exchange. Chief financial officer Florian Funck said the successful issuance strengthens the company's balanced debt maturity profile and long-term financing position, whilst demonstrating investor confidence in Sartorius' strategic direction.

Sartorius
May 6th, 2026
Sartorius completes placement of bond with a volume of 500 million euros

May 6, 2026 – Sartorius has successfully issued a bond with a volume of 500 million euros via its Dutch subsidiary Sartorius Finance B.V.. The issue was targeted at institutional investors and met with strong demand, being more than 4 times oversubscribed.

Associated Press
Mar 16th, 2026
Sartorius launches platform to cut CAR-T manufacturing costs by 90% and quadruple output

Sartorius has launched the Eveo Cell Therapy Platform, an integrated system for producing autologous cell therapies including CAR-T treatments. The modular platform can increase output up to fourfold in existing cleanroom space whilst reducing manufacturing costs by approximately 90 percent. The system integrates cell selection, activation, gene modification, expansion and final formulation into a closed system. Its compact design allows a single operator to process eight patient batches simultaneously in the space traditionally needed for two, potentially producing over 350 doses annually compared to today's 100 doses in the same footprint. A successful pilot with CDMO ElevateBio validated the platform's real-world applicability. Sartorius will begin taking orders in September 2026, with first deliveries expected in 2027.